Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clopidogrel On Top of Aspirin For the Prevention of New Onset Migraine Headache Occurrence Following Transcatheter Closure of Atrial Septal Defects: A Prospective Randomized Trial (the CANOA Study)

Trial Profile

Clopidogrel On Top of Aspirin For the Prevention of New Onset Migraine Headache Occurrence Following Transcatheter Closure of Atrial Septal Defects: A Prospective Randomized Trial (the CANOA Study)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel (Primary) ; Aspirin
  • Indications Embolism and thrombosis; Migraine
  • Focus Therapeutic Use
  • Acronyms CANOA

Most Recent Events

  • 09 Nov 2015 Primary endpoint has been met. (Mean number of monthly migraine days per patient within the 3 months following transcatheter ASD closure.)
  • 09 Nov 2015 Results published in the JAMA: the Journal of the American Medical Association
  • 09 Nov 2015 Status changed from active, no longer recruiting to completed, according to results published in JAMA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top